CytomX Therapeutics (NASDAQ:CTMX) and SIGA Technologies (NASDAQ:SIGA) Head to Head Survey

SIGA Technologies (NASDAQ:SIGA) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.

Risk & Volatility

SIGA Technologies has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for SIGA Technologies and CytomX Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SIGA Technologies	0	0	0	0	N/A
CytomX Therapeutics	0	3	3	0	2.50

CytomX Therapeutics has a consensus price target of $5.77, suggesting a potential upside of 340.65%. Given CytomX Therapeutics’ higher possible upside, analysts plainly believe CytomX Therapeutics is more favorable than SIGA Technologies.

Valuation and Earnings

This table compares SIGA Technologies and CytomX Therapeutics’ revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SIGA Technologies	$157.02 million	3.94	$68.07 million	$1.10	7.91
CytomX Therapeutics	$101.21 million	1.01	-$570,000.00	$0.20	6.55

SIGA Technologies has higher revenue and earnings than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than SIGA Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares SIGA Technologies and CytomX Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SIGA Technologies	48.55%	51.84%	38.41%
CytomX Therapeutics	13.87%	-30.70%	8.10%

Institutional & Insider Ownership

55.4% of SIGA Technologies shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 1.5% of SIGA Technologies shares are owned by company insiders. Comparatively, 7.0% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

SIGA Technologies beats CytomX Therapeutics on 8 of the 13 factors compared between the two stocks.

About SIGA Technologies

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

About CytomX Therapeutics

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.